Breast cancer is the most frequently occurring malignancy in women. It is characterized by a high mortality rate. For the purpose of detecting this life threatening disease, research efforts are being made worldwide to exploit new technologies, to improve the detection accuracy of current devices and to develop new detection devices, comprehensive diagnostic procedures, and protocols. One such technology that is gaining popular attention over the recent years is the usage of electrical characteristics of the breast tissue to differentiate normal and cancerous tissues. Most of the devices using this technology are currently being used as adjunct diagnostic tools to improve the detection accuracy of established techniques like mammography and ultrasound. Also, early detection of breast cancer can help save many thousands of lives every year and can also reduce unnecessary healthcare expenditure caused by advanced stage treatment options. Hence, more research is also being done to adapt these devices into screening tools for early detection of breast cancer.
Introduction
The United States National Cancer Institute has estimated that one in eight women will be diagnosed with breast cancer at some point of time in their lives (1). In spite of advances in the diagnosis and treatment of breast cancer, it still continues to be the cancer with a high mortality rate because of the lack of highly accurate detection techniques. Every available detection technique has its own advantages and limitations. Mammography (MG) is currently the most effective and widely used technique for breast cancer detection. Even though MG has demonstrated good performance and fast patient throughput in older women, it is not very effective in detecting cancers in younger women (less than 40 years of Technology in Cancer Research & Treatment, Volume 7, Number 4, August 2008 age) who have greater breast density. In a study conducted by Carney et al. (2) , MG recorded a sensitivity of 87% and specificity of 96.9% for women with fatty breasts. But for younger women with extremely dense breasts, the sensitivity of MG was only 62.9% and the specificity was 89.1%. This implies that the sensitivity increases with age and with less denser breasts. Moreover, if MG is used at such an early age, there will be increased radiation exposure. As a result, for younger women, generally, breast self examination, Clinical Breast Examination (CBE) and ultrasound are the recommended procedures. But, by the time CBE detects a cancer, the cancer is at an advanced stage (3). Ultrasound is frequently used to evaluate breast abnormalities that are found with screening or diagnostic MG or during a physician performed CBE. The advantages of this procedure include its flexibility to allow for repetitive scanning of the affected area, effectiveness in distinguishing solid lumps and cysts, safety, painlessness and its use as a tool for biopsy needle placement. But it is not as efficient in imaging microcalcifications as MG. Microcalcifications are often the first indication of breast cancer. Breast Magnetic Resonance Imaging (MRI) is useful when women have implants or suspected multifocal carcinoma (4). Though it has a very high sensitivity and is recommended for high-risk patients, specificity is low and it is more time consuming and expensive.
Owing to the inherent limitations of the existing devices currently being used in the detection of tumors, women are being subjected to unwanted biopsies resulting in emotional trauma and increased healthcare expenditure. Hence, several techniques such as Microwave Imaging (5), MRI based Elastography (6), Thermography (7), Optical Mammography (8), Electrical Impedance Tomography (EIT), Electrical Impedance Scanning (EIS), and electropotential based technique are currently being researched for efficient detection of potentially curable early stage cancers. Among these techniques, those based on the electrical characteristics (3, (9) (10) (11) (12) (13) (14) (15) (16) (17) have become a topic of great interest in the research field. Since the 1920s many research studies have concluded that malignant breast tumors have significantly different electrical impedance or electropotential values compared to those of normal tissues and benign lesions. The commercial devices described in this review use these findings to detect the cancerous breast tissues.
The main objective of this review is to introduce to the readers the capabilities and limitations of these devices. Firstly, an overview of the electrical impedance and electropotential characteristics of normal and malignant breast tissues is presented. Secondly, the efficacy of the available commercial devices such as T-Scan 2000, T-Scan 2000ED, Biofield Diagnostic System (BDS), MEIK, and Z-Tech System in effective breast cancer detection is accessed using the clinical trials carried out to date. Finally, the limitations and future enhancements required to improve the sensitivity and specificity of these devices are discussed.
Electrical Characteristics of Breast Tissue
This section provides an overview of the impedance and electropotential characteristics of human breast tissue and summarizes some of the most relevant studies conducted to analyze these characteristics.
Electrical Impedance of Breast Tissue
Biological tissues have the capacity to conduct an electric current and hence have an impedance parameter associated with them. The measurement of this impedance has found immense applications in cardiac cycle imaging (18), pulmonary ventilation imaging (19), imaging functional activity of brain (20), gastrointestinal function monitoring (21), hyperthermia monitoring (22), breast cancer detection, and skin cancer detection (23) . Tissues consist of cells and extracellular medium. The cells are made of cell membrane and intracellular medium. Both extracellular medium and intracellular medium consist of ionic solutions that are resistive in nature. The cell membrane is made of a lipid bilayer and proteins and is primarily capacitive. The impedance associated with this capacitance is dependent on frequency. At lower frequencies, the cell membrane acts as an insulator and hence current flows only through the extracellular space and the resulting impedance is largely resistive. At higher frequencies, the cell membrane starts conducting and hence the impedance is lower. Thus, it is evident that tissues exhibit frequency dependent electrical behavior (10). When the relative permittivity of the tissue is plotted against frequency f, one can observe three clearly distinguishable regions called the relaxation regions (24) (25) (26) (27) . They are called alpha (f < 1000 Hz), beta (1000 Hz < f < 100 MHz) and gamma (f > 1 GHz) regions. Blad et al. (28) suggested that alpha and beta regions are particularly useful for tumor detection measurements, since most changes between normal and pathological tissue seem to appear in this frequency range.
Over the years, several in vitro and in vivo studies have been conducted to study the dielectric properties of cancerous and non-cancerous breast tissues. The results of these studies are summarized in Table I . Since the commercial devices described in the later sections use operating frequencies that are below a few MHz, only the results of the studies covering this frequency range are presented in the table. These studies indicate that malignant tissues typically have higher conductivity, and/or permittivity, or lower impedivity when compared to the normal and benign tissues. In 1984, Pethig (39) attempted to review the dielectric properties of tissues and biomolecules. The review included various research studies which have, at a molecular level, tried to analyze the characteristics of malignant breast tissues that may be the reason for the difference in dielectric properties between normal and malignant breast tissues. Some of the characteristics stated include higher water content and sodium concentration of cancerous cells, different electrochemical properties of their cell membranes and reduced membrane potentials. Other studies (33, 34, 40) have also attributed the difference to the increased cellular water and salt content, altered membrane permeability, changed packing density and cell orientation of malignant tissues. The various research results summarized in the table suggest that electrical impedance is indeed a suitable parameter for tissue differentiation in the specified low frequency range. The readers may refer to the work by Hope et al. (12) and Zou et al. (13) for additional comprehensive technology reviews on electrical impedance based techniques for breast cancer detection. The commercial devices that use impedance as a parameter for breast cancer detection are T-Scan 2000, T-Scan 2000ED, MEIK, and Z-Tech system.
Electropotential Characteristics of Breast Tissue
Normal epithelial cells are electrically polarized by an ionic gradient across the cell membrane (41). The charge gradient between the apical and basolateral cell membrane is known as transepithelial electropotential (42). The electrical gradient across the membrane is maintained by the Na + /K + ATPase pump resulting in a transepithelial potential difference of 30 mV. As epithelial cells divide, the charge is dissipated, resulting in electrical depolarization. When breast cancer develops, these epithelial cells in the cancerous area divide far more rapidly than those in the normal tissue area, thereby leading to formation of pockets of relative depolarization. When the cancer becomes invasive, the ductal structure is destroyed, increasing the permeability of ions. These phenomena can produce a differential in electrical potential at the skin surface, which can be measured and used for diagnosis (43). Even if the cancerous lesion is situated deep inside the breast and is not palpable, it is still possible to dif- Table I Summary of the studies conducted to understand the dielectric properties of human breast tissue.
Authors, Year
Frequency range investigated Nature of study and results Fricke et al. (29), 1926 20 kHz They measured the parallel capacitance and resistance of the following excised samples from the breast -fat, gland, mastitis, fibroadenoma and carcinoma. They found significantly higher permittivity of the tumor tissue at 20 kHz as compared to the normal or benign tissues. Singh et al. (30), 1979 100 Hz -100 kHz They performed in vivo impedance measurements on female breasts with and without tumors. Their results showed that malignant tumors have higher relative permittivity and lower resistance than those of normal breast tissue. Chaudhary et al. (31), 1984 3 MHz -3 GHz They examined excised normal and malignant breast tissues and found that the conductivity and permittivity of malignant tissues are higher than those of normal tissues, especially at frequencies lesser than 100 MHz. Surowiec et al. (32), 1988 20 kHz -100 MHz They conducted in vitro dielectric studies in three different samples of breast tissues -the main tumor tissue, the tissue immediately surrounding the tumor, and the peripheral normal tissue. They found that the tumor tissues have a low frequency (100 kHz) conductivity around 2 to 4 mS/cm which is higher than the conductivity of normal tissue (below 1 mS/cm) and lower than that of the tissue surrounding the tumor (8 mS/cm). Morimoto et al. (33, 34), 1990 0 -200 kHz They measured the extracellular and intracellular resistances and membrane capacitance of breast tumors in vivo. They concluded that there are statistically significant differences between normal and cancerous tissues. However, it has been reported that malignant tumors have lowered capacitance compared to benign tumors. This is different from the results of the study conducted by Jossinet (36) and Fricke (33) which have recorded higher capacitance values for malignant tumors. Jossinet (35), 1996 488 Hz -1 MHz
The study examined six groups of normal and pathological breast tissues in vitro. The variability of impedivity within each group was assessed by statistical methods. It was found that the variability was smaller in adipose tissue, carcinoma and fibroadenoma above 10 kHz. Jossinet (36), 1998 488 Hz -1 MHz Using the same data from (35), it was found that the cancerous tissue differed significantly from fibroadenoma and mammary gland tissues by the modulus of impedivity up to 31.25 kHz and from the remaining tissue groups (connective tissue, adipose tissue, and mastopathy) by the low-frequency-limit resistivity and the phase angle from 125 kHz to 1 MHz. It was also observed that neither the impedivity, nor the low-frequency-limit resistivity nor the fractional power value was different between the groups of normal and benign tissues. Jossinet et al. (37), 1999 488 Hz -1 MHz Again using the same excised data collected for previous studies, they defined a set of eight parameters that could differentiate cancerous breast tissues from non-cancerous ones. They concluded that a combination of the parameters over various frequencies is necessary for the accurate differentiation among tissues. Chauveau et al. (38), 1999 10 kHz -10 MHz They conducted an in vitro study of normal and pathological breast tissues and observed significant differences in their dielectric properties. They have determined three indices based on extracellular resistance, intracellular resistance and membrane capacitance to differentiate between various tissue pathologies -normal, Invasive Ductal Carcinoma (IDC), IDC with stromal reaction and fibrocystic changes. ferentiate it, because cancer cells exhibit the concept of field carcinogenesis (44). It means that the abnormal cell growth is manifested even at a distance further away from the actual tumor leading to altered surface electropotentials over the entire field. These altered surface potentials can be indicative of pre-cancerous conditions, thereby warning the women about probable cancer risk (45). The BDS device uses these skin surface electropotentials for breast cancer detection.
Electrical Impedance Scanning (EIS) -T-Scan 2000 and T-Scan 2000ED
Electrical impedance scanning is a non-invasive in vivo imaging technique that is based on the different electrical conductivity and capacitance values of malignant and normal tissues. It produces an impedance map of the area under study based upon the spatial electrical characteristics of the area. A constant AC voltage is applied to the body between an array of sensing electrodes covering the surface of the body to be imaged, and a reference electrode is placed elsewhere on the body. The currents through the electrodes are then measured. With the current and potential known at each electrode, the impedance of each electrode is then calculated. These values are then projected to the surface and mapped as two-dimensional EIS images.
T-Scan 2000
The only United States Food and Drug Administration (FDA)-approved EIS device is the TransScan T-Scan 2000, manufactured by Mirabel Medical Systems (formerly Trans-Scan Research and Development Co.) (46).The pre-market approval from FDA was received in April 1999. This device has been approved to be clinically used as an adjunct to mammography in patients who have equivocal mammographic findings within ACR BI-RADS category 3 or 4. Hence, T-Scan images should be read and interpreted with respect to the corresponding MG images. A positive T-Scan finding in the vicinity of a suspicious lesion strengthens the necessity for biopsy, while a negative supports other management options. The T-Scan 2000 system, shown in Figure 1 , is a realtime, non-invasive, radiation-free, two-dimensional multifrequency imaging device for breast examination that maps the local distribution of tissue electrical impedance (46).
Data Acquisition:
In a T-Scan 2000 examination, an AC voltage of amplitude between 1 and 2.5 volts with frequencies spanning between 100 Hz and 100 kHz is applied between the hand-held reference electrode and the measuring probe placed over the breast. Although a large range of frequencies are used during the test, the interpretation is made only from the data obtained using the FDA approved frequency of 200 Hz (11). The examination is generally performed with the women recumbent, with the arm on the same side of the examined breast raised above the head. This position will flatten the breast as much as possible, allowing a good contact between the flat surface of the measuring probe and the underlying breast tissue. To obtain good contact between the probe and the breast surface, ultrasound gel is used. The measuring probe contains a multitude of electrodes arranged on a rectangular grid and each of the electrodes is held at virtual ground. The evoked currents are measured at the electrode pads. The calculated capacitance and conductance values are then mapped to gray scale values -higher values are mapped to lighter shades of gray and the lower values to darker shades -and then displayed on the monitor. For details on the operational principle of T-Scan, the readers may refer to the work by Assenheimer et al. (47) .
T-Scan 2000 can be operated in two modes (46). The targeted mode is used only for examining the location of an already known suspicious mammographic or sonographic lesion. In this mode, each of the sensors in the sensor array individually measures the impedance values at the targeted location.
The scanning mode or the standard resolution mode is used for acquiring the impedance maps of both entire breasts. The probe is moved in a pre-defined sequence over the entire breast. In both the modes, two three by three data sectors are recorded -one represents the capacitance map and the other is the conductivity map. The center of each map represents the values obtained from the nipple. The post processing algorithm used is described at a later section.
The imaging is real time and the probe can be moved over the breast to obtain the best possible image. There is also a provision for adjusting the gray-scale mapping levels to highlight and enhance certain features alone. Because breast cancer cells have a conductance higher than that of the normal breast cells, breast tumors may appear as bright white spots on the computer screen. According to cell properties, conductivity of nipple tissue is very high compared to the rest of the breast tissue, and hence a healthy nipple is represented as a bright white spot. Thus, when a normal breast is imaged using T-Scan, the only area that should appear as a bright spot is the nipple. If there are other bright spots in the image sectors, they may be due to a clinical finding, artifact due to skin lesions, or abnormal anatomy (46). A typical breast examination performed with the T-Scan 2000 system is shown in Figure 2 .
Advantages of T-Scan 2000 system
• Unlike MG, T-Scan requires no radiation or breast compression. To make data evaluation less subjective, the system calculates conductance and capacitance values and provides readout of the figures. Hence, T-Scan images require less interpretation when compared to MG images.
• The technique uses only low voltage levels and it is
non-invasive causing no discomfort to patients.
• The equipment is inexpensive and has low acquisition
time when compared to other techniques. • T-Scan can detect cancerous lesions as small as 3 mm in diameter (48).
Limitations of T-Scan 2000 system
• The scanner is not intended to be used on patients who have had a recent breast surgery at the targeted site and who have electric-powered implants. • The ultrasound gel used during the procedure may generate bubbles or unequal contact surface and unequal gel thickness between the probe and the breast surface, thereby inducing false positive results. The investigator has to be aware of these facts and avoid them.
• Artifacts created by interfering bones, muscles, and superficial skin lesions may appear as a bright spot mimicking lesions. Again, the investigator should avoid them. • The maximum depth of measurement is between 3 and 3.5 cm (13) and hence, lesions close to the chest wall may go undetected. • Since nipple appears as a bright spot, cancerous lesions (which also show up as a bright spot) directly behind the nipple are not always detectable due to the similarity in appearance. • Post-processing algorithms to automatically discriminate between benign and normal tissue are limited.
Clinical Trials:
The robustness and limitations of the T-Scan 2000 device and the algorithm used can be evaluated using the data obtained from clinical trials carried out over the past few years. Table II gives a brief summary of most of the trials and the respective results.
The visual interpretation of the recorded impedance maps by many researchers is not consistent as revealed by the large variation in sensitivity recorded in many clinical trials tabulated in Table II . In order to standardize the readings, an objective nonuser-dependent post processing algorithm was developed by Glickman et al. (58) . The main predictors of the algorithm are the crossover frequency and phase of the electrical impedance parameters recorded over the entire frequency range (100 Hz-5 kHz) at only the lesion and nipple region and not the entire breast. to the fact that a large percentage of the lesions in their study were located at a greater depth, not easily identifiable by EIS. They concluded that the LOS software setup provided better improvement over the usual T-Scan focal spot based method, especially for small malignant lesions and that EIS as an adjunct to ultrasound or MG may have a better clinical impact.
In another study by Fuchsjaeger et al. (61) in 2005, the negative predictive value of T-Scan 2000 in analyzing 128 BI-RADS category IV breast lesions was studied. The LOS software described earlier was used for the study. A very high negative predictive value of 97.1% was obtained. This indicates that instead of subjecting the BI-RADS IV lesions, which had negative EIS result to biopsies, the physician can treat these lesions as those belonging to BI-RADS III with confidence and ask the patient to come for a short-term follow-up. This can reduce the healthcare expenses to a great extent.
T-Scan 2000ED
T-Scan 2000ED is yet another device from the developers of T-Scan 2000. It received the CE mark in 2003 and is yet to receive the pre-market approval from FDA. It is intended to be used as a complement to clinical breast examination in asymptomatic women who are between 30 and 39 years of age for whom routine mammography is not recommended. It is based on the same technological principles as T-Scan 2000, but uses a different scoring algorithm that maximizes specificity so that it can be suitable as a screening tool. Dickhaut et al. (62) suggested that the measured impedance values are primarily related to generalized, premalignant, tissue-proliferative changes. This finding strengthens the suitability of EIS for use in screening younger women who normally don't have palpable lesions. Hence, this new device uses the data obtained from the entire breast and processes them in a manner to maximize specificity and minimize the number of false positives. Since electrical impedance tends to decrease with age, the decision threshold for this device was set at a higher level. This implies that the sensitivity of T-Scan 2000ED would be lower for older women. For more details on the algorithm, the readers may refer to the work by Stojadinovic et al. (3) .
The data acquisition procedure is similar to that of T-Scan 2000 except for the recording frequency. In T-Scan 2000ED, the conductance and capacitance values are recorded over a wide frequency range of 100 Hz to 1 GHz and used to cal- Studied the suitability of impedance measurements for breast cancer screening using a prototype to the T-Scan 2000 called Mammoscan.
No statistical results like sensitivity or specificity were reported.
TransScan group (46), 1995-1997 Carried out three studies to evaluate the effectiveness of T-Scan 2000 as an adjunct to MG.
In one blinded study, the sensitivity of 60% obtained using MG alone increased to 82% on using adjunctive T-Scan (combination of T-Scan and MG). The specificity increased from 41% to 57%. In another study using the targeted mode, the sensitivity and specificity were around 78% and 67% respectively. A higher sensitivity of 93.3% and specificity of 83.3% were achieved when targeted mode of T-Scan 2000 was used and results interpreted adjunctive to MG results. Scholz et al. (50), 2000 Conducted numerical simulations to determine the parameters that affect the impedance measurements.
The measured peak signal of a lesion of a fixed size at a fixed distance from the measurement plate decreased with increasing breast thickness. In the case of large breast, the electric field became inhomogeneous and the lesion signals kept decreasing with increasing surface area and edge effects also started appearing. Pertlet et al. (51), 2000 Investigated the correlation between hormonal factors and the false positive results associated with EIS using the T-Scan 2000 in 21 healthy pre-menopausal women.
Each woman was examined once per week for two menstrual cycles. The number of white spots that appeared in the T-Scan image varied with the menstrual cycle and had temporal instability. They concluded that the presence of these false positive spots did not strongly correlate with age, hormonal use (oral contraceptive use) or the electrical characteristics of the breast. Similar research in large varied population is necessary to conclude if these results can help to distinguish true positive and false positive spots on T-Scan images. Malich et al. (52), 2000 Conducted a study to evaluate the efficiency of the two operating modes of T-Scan 2000 on sonographically or mammographically suspicious lesions.
A sensitivity of 93.1% and specificity of 65.5% was achieved for the targeted mode. The standard resolution mode had lowered sensitivity of over 75% and specificity of 72.4%. This group concluded that EIS can be a valuable adjunctive tool especially when used in the targeted mode. Malich et al. (53), 2001 Evaluated the advantage of combining EIS, MG and ultrasound.
The addition of EIS to MG and ultrasound increased the sensitivity from 86.4% to 95.1% while decreasing the accuracy from 82.3% to 75.7%. They concluded that EIS is a promising technology since it increases the sensitivity when combined with MG and/or ultrasound; but its clinical use depends on the reduction of false positive results.
culate the final result. The output of T-Scan 2000ED is presented on a binary indicator bar (green indicates negative and red indicates positive). A positive result indicates that the woman is at a higher cancer risk and helps the physicians decide on further breast examination tests that are required.
In 2005, Stojadinovic et al. (3) , attempted to evaluate the efficiency of T-Scan 2000ED. Sensitivity and specificity in women younger than age 40 using this new device was 50% and 90%, respectively. In 2006, Stojadinovic et al. (14) conducted a two-arm, prospective, multi-site clinical trial to evaluate the use of EIS to identify younger women at high risk of cancer. The sensitivity arm had 189 women aged 30-45 years with suspicious breast abnormality who underwent CBE and EIS (T-Scan 2000ED) prior to biopsy. A sensitivity of 38% was recorded in this arm. In the specificity arm a total of 1361 women aged 30-39 years were enrolled for the study. A high specificity of 95% was recorded as was expected in a T-Scan 2000ED examination. These results were confirmed by another prospective, two-cohort trial conducted by Stojadinovic et al. (63) in 2008. It was found that T-Scan 2000ED was able to identify a subset of young women with a relative probability of breast cancer almost five times greater than in the population of young women at large. With EIS, a sensitivity and specificity of 81% and 63% were observed. Since the results of EIS were found to be comparable to MRM results, the suggestion was that EIS can be used as an adjunctive technology in situations where MRM cannot be used. Martin et al. (55), 2002 Carried out T-Scan 2000 examination on mammographically suspicious lesions to understand the relation between the histopathology of abnormal breast conditions and intensity, depth and multiplicity of EIS signals.
Multiple EIS signals were observed more frequently in cases with malignant biopsy than in benign biopsy cases. The EIS signal intensity did not decrease with the increasing depth of the lesions (in the depth range 0.5-5.5 cm). This is contradictory to the results published by Scholz et al. (50) . This difference may be attributed to the geometrical breast model errors and simplicity of the breast conductivity distribution assumed in the numerical model. This group also observed that benign proliferating lesions were a reason for false positive results. Piperno et al. (56), 2002 Conducted a clinical trial to evaluate the use of electrical impedance measurements to determine the estrogen activity in 86 postmenopausal women.
The conductance and capacitance values decreased with the increasing number of years from the onset of menopause. It was noticed that nipple conductance measured at 200 Hz was higher in women taking Estrogen Replacement Therapy (ERT) than those who weren't taking ERT, thereby indicating that EIS can be a suitable method for predicting estrogen activity. Malich et al. (48), 2003 Studied the influence of size and depth on the accuracy of targeted mode of T-Scan 2000.
The spots were clearly visible in lesions at a depth of 11-25 mm. Large homogeneously structured lesions did not present a visible focal spot because the conductance of the measuring field increases and hence the relative changes in the larger field become smaller. In such cases it has been observed that, if the border of the lesions instead of the center were examined, the sensitivity obtained will be comparable to that obtained using other lesion sizes. They concluded that the software should have options for depth adjusted impedance determination and should also take into account the size parameter. Since ultrasound helps in measuring the size and depth of the lesions and thereby aids in better interpretation of EIS results, it has been suggested that ultrasound should be performed prior to EIS. Malich et al. (11), 2003 Conducted the EIS study on 240 women with 280 lesions and presented a review on the clinical value and limitations of EIS.
An overall sensitivity of 80.5% and specificity of 64.7% were recorded. They observed the following • When the examination frequency was increased to higher values the bright spots switched into black areas. • It was difficult to interpret the lesions located close to the chest wall due to contact problems. • A large number of malignant lesions did not register a focal increased value of capacitance; the reason for this has to be investigated. • The absolute values of the conductivity and capacitance recorded largely depend on the pressure between the breast and the scanner and critically depend on the operator's skill and experience. Zhenyu et al. (57), 2005 Attempted to study the parameters influencing EIS imaging using simulations.
When the tumor was close to the measuring electrodes, the electrical disturbance signal was large and the resulting image was clear and vice versa. Keeping the distance of the tumor from the measuring electrodes constant, it was found that with increasing tumor size the contrast of the resulting image was lost. Poor contact between the measurement probe and skin surface resulted in artificial imaging.
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Since the device is not intended to be used for lesion localization, if a patient is found at a higher risk, she should undergo other diagnostic procedures for further evaluation. Thus, T-Scan 2000ED is intended to be used as a screening tool to select at-risk young women for highly sensitive breast cancer diagnostic tests.
Electrical Impedance Tomography (EIT) -MEIK
In EIT, a large number of impedance measurements are made from electrodes placed on the body surface and the results are processed by a computer to produce reconstructed tomographic two or three dimensional images of the impedance. In any impedance measurement technique, a current must flow in the tissue and the resulting voltages will be measured. This applied current will be referred to as the excitation current. Almost all EIT systems use constant current sources, and measure voltage differences between adjacent pairs of electrodes. There can also be voltage driving mode wherein voltages are applied and the currents are measured. To obtain an image with good spatial resolution, a number of such measurements are obtained by applying different current distributions to the body, and repeating the voltage measurements. These set of measurements are then used to generate the tomographic image by complex image reconstruction techniques. In EIT, it is possible to inject a range of currents at different frequencies (9). A variety of experimental EIT systems have been developed worldwide. For detailed information on EIT, the readers may refer to the work by Bayford (9) and Holder (10). PKF "SIM-technika" Ltd., a company in Russia, developed a commercial EIT device called МEIK (Mammograph Electrical Impedance Komputer) (15). This device received the CE mark in 2007. This section describes the device features and the clinical trials carried out to evaluate the accuracy of this device.
Data Acquisition
The MEIK system enables the user to visualize the static three-dimensional distribution of electrical conductivity in the breast tissues. For scanning purpose, the device utilizes a constant current of 0.5 mA at 50 kHz. The scanning probe consists of 256 electrodes, arranged in a matrix form (Fig. 3) . Initially, two disposable gel electrodes are attached on the inside of the wrist of the hand nearest to the breast to be examined. During examination, the scanning probe is pressed against the breast so as to increase the number of electrodes in contact with the breast and to decrease the thickness of the tissue layer to be measured. Once the scanning process is initiated by pressing a button, each of the 256 electrodes, one at a time, successively injects current into the examined area and the corresponding surface electropotentials are recorded. This entire scanning process takes about 35 seconds (15). The 3-D distribution of the electrical conductivity is then reconstructed by using the method of weighted back projections along the equipotential surfaces of the electrical field. Seven tomographic planes are reconstructed within a time span of 20 seconds. The resulting image represents tissue conductivity along a grey scale from dark to light, which represents low to high conductivity. Tumors and nipple areas, being highly conductive, appears as bright areas. The processing software has many inbuilt capabilities (15) such as numeric data filtering, color scaling, contrasting, highlighting of a specific area and also an option for comparing the electroconductivity of the left and right breasts using the values of the percentage of spread in the electroconductivity distribution.
Advantages of MEIK system
• Since the obtained image gives a 3-D view of the examined tissue (unlike T-Scan which gives a 2-D image), it is possible to identify and differentiate, to a certain extent, the parts like ribs, muscle, skin lesions, and the actual suspicious lesion based on their location on the seven image slices. • Like T-Scan, MEIK does not require any radiation or breast compression and it is also non-invasive causing no discomfort to patients. The test is also fast and easily repeatable. • The equipment is inexpensive and there are also no expensive disposables. • The result interpretation is less subjective and hence there is very less inter-observer variation. • According to the existing statistics (15), the smallest tumor detected by MEIK is around 3-5 mm. • The maximum depth of measurement is up to 6 cm (64), which is suitable for analyzing deep lesions.
Limitations of MEIK system
• It is indicated that the MEIK system can be used for screening purposes (15). More evaluations are needed to establish its efficiency as a screening tool. • Enlarged breasts might affect the quality of examination due to limited scanning depth. • Like T-Scan, it is difficult to differentiate any lesion that is in close proximity to the nipple.
Clinical Trials
The earlier version of MEIK, termed as Breast Cancer Detection Device (BCDD) was developed in the Institute of the Radio-Engineering and Electronics of the Russian Academy of Sciences with the support of Technology Commercialization International, Inc. (USA) (64). This system, operating at a frequency of 10 kHz and using 0.2 mA current, used 256 electrodes arranged in a square matrix and also used the method of weighted back projection to reconstruct the 3-D conductivity distribution. In the clinical trial conducted by Cherepenin et al. (64) using this device, 21 women with tumors in one breast were examined. The images called Electrical Impedance Mammograms (EIM) were reconstructed every 8 mm down to a depth of 6 cm. They found that 86% of the diagnoses made by BCDD were fully or partially consistent with diagnoses made by other tests. They have attributed the data mismatch to enlarged breasts, which might affect the results due to limited scanning depth and also to the effects of medical treatments such as puncture, biopsy, or x-ray therapy done before the BCDD test in certain cases. They found a significant difference in electrical conductivity between the normal and tumor affected breasts at all scanning planes. In the regions estimated solely to correspond to tumor, increased conductivity was observed at all scanning planes.
In another clinical trial conducted by Cherepenin et al. (65) , the same BCDD system (0.5 mA, 50 kHz) was used with changes made to the scanning probe. Instead of the square matrix, a round matrix was used to allow more electrode contact with the skin. Also the usage of the same number of electrodes in a round matrix increased the electrode density and thereby increased the image resolution. In this study, they focused on evaluating the possibilities of using EIT in the examination of mammary glands with different hormone status. They found that the EIT images were the same at the first and second phases of the menstrual cycle and also during pregnancy. During lactation, they observed light colors at the center of the image reflecting the increased conductivity due to the milk content in the ducts. The EIT images at menopause were distinctly different from the other images with the increased presence of lighter areas. They also observed similar conductivity levels at the first and second phase of a 28-day menstrual cycle and increased conductivity in postmenopausal breasts. The presence of lighter areas in the EIM of postmenopausal breasts and their increased conductivity can be attributed to their increased fat and connective tissue content. They concluded that all these observations about the healthy breasts at various physiological periods can serve as a benchmark when pathological breast tissues are evaluated at a later stage.
According to Campbell et al. (66) , studies are being conducted in the Czech Republic and Italy and the results are yet to be published. Korotkova et al. (67) described the procedure that is most suitable for interpreting the EIM images. They enlisted various visual details and quantitative parameters that might be valuable in accessing the images. Sotskova et al. (68) attempted to determine the particularities of the EIM images in different forms of infiltrative breast cancer. All these image based information can be put to good use only after more elaborate clinical studies report the sensitivity and specificity values. Currently, the data provided by the manufacturer indicate that the device has a sensitivity of 92% and specificity of 99% (15).
Z-Tech System
The Z-Tech Breast Cancer Detection System developed by Z-Tech Incorporation also uses electrical impedance to detect breast cancer. But it is currently limited to investigational use in clinical trials only (16) . No commercial distribution of the device has been reported so far. We have included the system description in this review so as to be complete in presenting details about the many different ways of using electrical impedance for breast cancer detection. The Z-Tech system is also non-invasive and radiation-free. It uses disposable, single-use flower petal shaped disc (Z-Tech SuperStellate Sensors) ( Fig. 4 ) that can be attached to the breast under test. The disc has a hole in the center to accommodate the nipple. Each disc has 12 petals (electrodes) and each petal fits the contour of the breast and sticks onto the skin with the help of an adhesive. Over 300 combinations of electrodes, one combination at a time, are selected for impedance measurements throughout each breast. The operation is based on the fact that the right and left healthy breasts exhibit similar electrical properties and the device attempts to compare the impedance values acquired from both the breasts to detect any abnormalities. This principle is called as Homologous Electrical Difference Analysis (HEDA) (16). If one of the breasts has an abnormality, then difference in impedance between the two breasts become higher. Z-Tech has established benchmarks for HEDA numerical values so that a result below the calculated cut-off point is diagnosed as HEDA Negative (no breast cancer), or if above the cut-off point, as HEDA Positive. Z-Tech system does not display any image of the breast. It is primarily a screening technique, like T-Scan 2000ED, that merely suggests if the woman has to take up further diagnostic tests or not. It has been reported that Z-Tech has completed clinical trials on 3,500 subjects at 28 different sites. Preliminary results indicate that the false positive rates have been lesser than mammography, especially in younger women (< 50 years of age) (69). Comprehensive results are expected to be published soon. Currently trials are in progress to achieve FDA's pre-market approval.
Biofield Diagnostic System (BDS)
The Biofield breast cancer diagnostic system, developed by Biofield Corporation, USA (17) (Fig. 5) , is based on differentiating cancerous lesions from non-cancerous lesions with the help of measured skin surface electropotentials. Unlike the other devices described earlier that measure active applied alternative current, BDS measures the passive skin-surface DC electropotentials. The Biofield test provides an immediate, objective assessment of the breast tissue in vivo. This device received the market approval from the European Union (CE mark) to be an adjunct to physical breast examination or relevant imaging modalities in patients less than 56 years of age with palpable lesions.
Data Acquisition
The BDS device is a desktop sized electronic device with a display screen, keyboard, printer, and patient cable. The patient cable actually has two cables, one for each breast, with labeled sensor leads. Each of the nine leads on each cable should be connected to nine single-use sensor pads that are pre-gelled. Depending on the center of the lesion, these sensors are arranged using specific breast maps described in the operation manual. One diagnostic sensor is placed over the center of the suspicious lesion and four additional sensors are placed outside the margins of the lesion, superior to, inferior to, medial to, and lateral to the sensor placed over the lesion. Two additional sensors are placed in the center of the two quadrants adjacent to the symptomatic quadrant and one sensor is placed in the quadrant diagonal to the quadrant with the test lesion. This pattern of sensor placement is then replicated in a mirror image form on the contralateral breast. This is to make sure that the opposite breast serves as a control for evaluating the asymmetry between the two breasts. Reference sensors are then placed just below and between the breasts. After the test is completed the sensors are removed from the patient and the results are printed. Once the sensor impedance values are acquired, the device calculates and outputs a BDS score between +5 and -5. This score is combined with the prior LOS values (assigned by the physician after clinical diagnosis using ultrasound, mammography and/or CBE) using a map (43), to determine an adjusted LOS value which will provide guidance for further diagnostic procedures.
Advantages of BDS
• The test is non-invasive, radiation-free causing no discomfort to the patient. • Without any visual output, the test results are more objective compared to T-Scan and MEIK. • BDS test is fast, can be repeated as often as needed and it is a cost-effective procedure.
Limitations of BDS
• The accuracy of the sensor placement is dependant on the operator as there are no images to guide the operator for accurate placement.
Clinical Trials
BDS is still not available for commercial distribution in the United States because it is yet to receive FDA's pre-market approval. BDS received the CE mark after conducting a clinical trial on a total of 463 patients falling within the age bracket of 18-55 years. There were 299 patients who underwent biopsies of which 150 were benign and 149 malignant. A comprehensive algorithm implemented in this study using the Biofield test yielded a sensitivity of 98.7% and specificity of 52.2% (43) . It was also demonstrated that BDS increases the malignancy detection by up to 20-29% compared to current diagnostic techniques such as mammography and ultrasound.
In a pivotal study conducted by BDS for the purpose of results submission to FDA (43), subgroup analyses were done to assess the effect of age, lesion palpability and size, and nature of cancer (invasive or non-invasive) on the BDS results. It was found that BDS provided added cancer detection (increases of 22% or more) for all age groups compared to mammography. Hence, the adjunctive use of the BDS for all age groups is positive and supported. BDS also detected 33.2% more palpable cancers than mammography alone. The results showed that higher predictive information occurred in women with palpable lesions. In the case of lesion size, cancer detection remained high (90% or higher) for all ranges of lesion sizes, the smallest being less than 0.5 cm. The sensitivity with BDS versus mammography alone increased for both non-invasive (40% higher) and invasive lesions (23% higher). All the above results prove that BDS provided higher effectiveness within these difficult sub-populations, and hence, the adjunctive effectiveness of BDS to mammography is promising and supported. Silvestrini et al. (70) reported that the BDS score correlated with the Thymidine labeling index in 84 patients with cancers at a test conducted in Istituto Nazionale Tumori in Milan, Italy. In another study in Japan, 101 women were tested using BDS and the sensitivity and specificity values were 90% and 60%, respectively (71). In a clinical trial conducted by Cuzick et al. (45) , 661 patients above the age of 18 years (18 to 90 years), who had a suspicious lesion scheduled for excision biopsy, underwent the BDS test, which was conducted at eight centers in five European countries. It was concluded that BDS provided highly significant discriminatory information for women with palpable lesions. This group developed a depolarization index (BDS score) based on the electropotential differences and age. This index is a linear combination of the surface voltages derived from sensors over the suspicious lesions, median voltages of the three uninvolved quadrants of the symptomatic breast and the range of voltages of the asymptomatic breast plus the patient age. The median depolarization index was 0.40 for nonproliferative benign lesions; 0.53 for proliferative benign, and 0.64 for cancer. Using age and this index, a specificity of 55% was obtained at 90% sensitivity for women under 56 years with palpable lesions. In the case of non-palpable lesions, only a minimal discrimination was achieved. The reason for this is attributed to the difficulty in accurate sensor placement over the non-palpable lesions.
Ki-67 antigen expression is a commonly used invasive method for distinguishing aggressive cancers with high proliferative activity and malignant lesions that have proliferative activity similar to benign lesions (which appear less than 10% of the times). To confirm that the BDS test measures net electrical activity related to cellular proliferation as determined by this Ki-67 antigen expression, a prospective study of 103 consecutive patients, with palpable breast lesions and scheduled for open biopsy, was conducted (72). In this study, the average Ki-67 antigen expression values were compared with BDS score using Spearman and Wilcoxon rank correlation. The results showed a positive correlation with the Ki-67 antigen expression. The post market surveillance study (43) was carried out as a routine practice after BDS obtained the CE marking. Three hundren eighty-nine women participated in the test and 90% sensitivity and 40% specificity were recorded.
Discussion and Conclusion
Breast cancer is the most common cancer among women. Even though the probability of occurrence is less in women less than 40 years of age, it is still necessary to develop efficient detection techniques to detect cancer in this subset of women. This will not only improve the emotional wellbeing of the women, but also improve their social and economic contribution. Hence, development of detection tools that have high reliable accuracy in women of all age groups is of primary importance. Breast cancer detection using electric characteristics of breast tissue has been under study for over 80 years now. Initially, research was on the study of the capability of electrical impedance or biopotentials to differentiate malignant from benign or normal breast tissues. Since many in vitro and in vivo studies could establish this capability, several groups around the world designed devices to measure electrical impedance or surface biopotentials from the breast and developed algorithms using these values to determine the presence of cancer. Among them, as reviewed in earlier sections, T-Scan 2000ED, T-Scan 2000 and BDS have demonstrated good detection accuracy that is clinically significant with regards to their intended use.
More clinical trials are needed before one can conclude the efficiency of MEIK and Z-Tech system. Thus, electrical characteristics based technique can be regarded as an effective tool for breast cancer detection because of its clinically acceptable efficiency and its many advantages like painlessness, easy repeatability, less examination time, more objective interpretation, and high safety that allows the test to be recommended for young women and old women alike.
But there are certain limitations that need to be addressed. On the electronics side, there are practical concerns on the low resolution, and the trade-off between complexities, speed and noise levels in the electronics, and electrode connections.
To improve the resolution, the number of electrodes should be increased. But the size of the breast will prove to be a major constraint in determining the number of electrodes. On the clinical side, it is evident that there are wide differences among sensitivities and specificities recorded. These differ- ences may be attributed to the difference in the method of recruiting patients, effect of influencing parameters like the age and hormonal status of the participants, size and depth of lesions, and finally changing levels of operator skill and experience in data acquisition and interpretation. The research community should, therefore, frame a standardized study protocol and conduct multicenter studies worldwide so that the results from all the studies can be compared and important conclusions and enhancements can be made.
Considering individual device specific improvements for T-Scan 2000 there are certain aspects that need further development.
• The frequency response of both normal and pathological breast tissue needs to be better understood and an optimal frequency range has to be decided for tissue differentiation. Currently, only the FDA approved reading frequency of 200 Hz is being used. The device response for a wider range of frequencies (up to 1 MHz) has to be tested (48). • Special filtering software can be developed to indicate the artifacts caused by bubbles, interfering bones, muscles and skin lesions (52). • Lesions close to chest wall or those directly beneath the nipple may go undetected or are difficult to interpret. Hence, different electrode placement techniques have to be researched upon. • Since T-Scan 2000 is intended to be used as an adjunct modality, it does not have to localize lesions. But three dimensional EIS solutions can be developed to help in lesion localizations for biopsy studies. • The EIS software should take into account lesion size and depth information for better diagnosis (48). • Piperno et al. (49) have suggested that EIS can be an indicator of estrogen activity. More clinical trials are necessary to study the influence of hormones on the EIS results.
As for T-Scan 2000ED, it is easy to use, non-invasive, lowcost, radiation-free, characterized by a binary outcome for easier, quicker, and objective interpretation. Moreover, the algorithm used is tuned for screening cancer in younger women and is not altered by the density of the breasts. But since this device does not locate the lesion in EIS positive cases, the women must undergo other breast imaging tests to confirm the diagnosis. Further large scale multicenter clinical trials are needed before one can use this screening device to confidently rule out or detect cancers in young women.
The BDS device also has the same advantages as that of T-Scan 2000. BDS can be improved if the following issues are addressed.
• The system is not intended to be used for screening purposes. It is currently used for differential diagnosis of localized suspicious lesions. The field carcinogenesis concept explained earlier can be exploited to develop BDS for screening purposes when women do not have visible symptoms. Even though there have been pilot studies (73), which used non-directed sensor array to measure the electropotentials independent of lesion location, many more studies are required to establish BDS as a screening modality. • Better sensor placement technology is necessary for achieving good diagnostic accuracy. The current software indicates misplaced sensors after the data has been collected. But it would be better if the software indicates any misplaced sensors or sensors with less skin contact at an earlier stage. • As highlighted earlier, BDS has a capability to measure the net electrical activity related to cellular proliferation as demonstrated by its high positive correlation with Thymidine labeling index and Ki-67 antigen expression. This finding can be utilized to evaluate the tissue proliferation before, after and during cycles of cancer therapy (74).
The effectiveness of MEIK has also been demonstrated by a few clinical trials. Even though it provides a 3-D view of the electroconductivity characteristics, its efficiency in locating malignant tumors for biopsy is yet to be studied. The screening capability of MEIK also needs further evaluation. More studies are necessary to determine the clinical efficiency of both MEIK, and the Z-Tech systems. The availability of the devices like T-Scan 2000, 2000ED, BDS, MEIK and Z-Tech system proves that electrical characteristics based breast cancer diagnosis is a promising technique that is continually being researched and developed. Due to their simplicity in implementation and interpretation, either these devices can undergo further enhancement or new devices along these lines could be developed to be used as standalone/adjunct screening and diagnostic tools for breast cancer detection.
